Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC.INTS · Entity 7853 | Principal Accounting Officer | July 16, 2026 | July 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTENSITY THERAPEUTICS, INC.
Report date July 16, 2026 · Filed July 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $4.90 · Expires 2036-07-16 | Direct | 11,000 |
Reported balance
After 2026-07-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-16 · Grant · Acquired 11,000 · Balance 11,000 F1: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 20, 2026 20:02 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantStock Option (right to buy Common Stock) · Derivative | 11,000 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001895944-26-000008 · wk-form4_1784577777.xml · derivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2036-07-16 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2027. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:09 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantCommon Stock, $0.0001 Par Value | 3,688 | $3.49 | $12,852.68 |
DisclosureSEC source: 0001895944-26-000006 · wk-form4_1782936560.xml · nonDerivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,102 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's Amended and Restated 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2026. F3 · balance_after: On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:03 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantCommon Stock, $0.0001 Par Value | 8,918 | $0.26 | $2,336.52 |
DisclosureSEC source: 0001895944-26-000003 · wk-form4_1767647011.xml · nonDerivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,354 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on July 1, 2025. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:03 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantCommon Stock, $0.0001 Par Value | 69,745 | $0.26 | $18,203.45 |
DisclosureSEC source: 0001567264-25-000066 · wk-form4_1751486573.xml · nonDerivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,436 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2025. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:21 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantStock Option (right to buy Common Stock) · Derivative | 100,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001567264-25-000035 · wk-form4_1746562857.xml · derivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-05-02 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in five, equal, annual installments, beginning on May 2, 2025. Read SEC document |
| May 02, 2025 Filed May 6, 2025 20:07 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantStock Option (right to buy Common Stock) · Derivative | 100,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001567264-25-000029 · wk-form4_1746561910.xml · derivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-05-02 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in five, equal, annual installments, beginning on May 2, 2025. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 20:22 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantStock Option (right to buy Common Stock) · Derivative | 70,028 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001895944-24-000014 · wk-form4_1729714943.xml · derivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,028 Underlying: Common Stock · 70,028 shares Expires 2034-10-21 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in five, equal, annual installments, beginning on October 21, 2024. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 11:26 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | Exercise / conversionStock Option (right to buy Common Stock) · Derivative | 1,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001895944-24-000011 · wk-form4_1717759566.xml · derivative · entry 2 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 1,000 shares Expires 2027-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable as of March 27, 2021. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 11:26 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | Exercise / conversionCommon Stock, $0.0001 Par Value | 1,000 | $4.00 | $4,000.00 |
DisclosureSEC source: 0001895944-24-000011 · wk-form4_1717759566.xml · nonDerivative · entry 1 Wesolowski John M · CIK 0001895944 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Due to an inadvertent error, the Form 3 filed by the Reporting Person on June 29, 2023 incorrectly reported the amount of securities beneficially owned. This inadvertent error caused the amount of securities beneficially owned to be understated by 691 shares. The new amount reported in Column 5 reports the correct amount of securities beneficially owned following the reported transaction. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 23:06 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantStock Option (right to buy Common Stock) · Derivative | 25,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001213900-24-020835 · ownership.xml · derivative · entry 1 Wesolowski John M · CIK 0001895944 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-03-06 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on March 6, 2025. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 20:11 UTC | INTENSITY THERAPEUTICS, INC. INTS · Entity 7853 | GrantStock Option (right to buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $6.43 | $0.00 |
DisclosureSEC source: 0001213900-23-058840 · ownership.xml · derivative · entry 1 Wesolowski John M · CIK 0001895944 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-07-19 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., according to the following schedule: 25% will vest on July 19, 2023, and the remaining 75% will vest in three, equal, annual installments, beginning on July 19, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.